Pharmacokinetics of bronchial artery infusion of mitomycin in patients with non-small cell lung cancer

The pharmacokinetics of bronchial artery infusion of 20 mg (11.4–14.0 mg/m 2) mitomycin was studied in 14 patients with non-small cell lung cancer (NSCLC). The mean elimination half-life was 34.3 min (range 6–72), and the area under the plasma concentration-time curve (AUC) was 166 ng h/ml (39–312)....

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of cancer & clinical oncology Vol. 27; no. 8; pp. 1046 - 1048
Main Authors Shimizu, Eiji, Nakamura, Yoichi, Mukai, Jun-nosuke, Tani, Kenji, Yamashita, Takashi, Hojo, Fumihiko, Hashimoto, Yoshihiro, Ogura, Takeshi
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.01.1991
Subjects
Bronchial Arteries
Carcinoma, Non-Small-Cell Lung - blood
Half-Life
Humans
Injections, Intra-Arterial
Lung Neoplasms - blood
Mitomycins - pharmacokinetics
Online AccessGet full text

Cover

More Information
Summary:The pharmacokinetics of bronchial artery infusion of 20 mg (11.4–14.0 mg/m 2) mitomycin was studied in 14 patients with non-small cell lung cancer (NSCLC). The mean elimination half-life was 34.3 min (range 6–72), and the area under the plasma concentration-time curve (AUC) was 166 ng h/ml (39–312). The mean maximum plasma drug concentration ( C max) was 178 ng/ml (12–540) and back-extrapolated plasma drug concentration was 308 ng/ml (17–1423). The mean volume of distribution in the one-compartment model was 0.183 l/kg (0.010–0.887) and the rate constant for unchanged drug appearing in the urine was 1.91/min (0.57–7.27). There was considerable variation among individuals with respect to the pharmacokinetics of mitomycin, and the mean C max and AUC were lower than those reported after intravenous administration.
ISSN:0277-5379
0959-8049
DOI:10.1016/0277-5379(91)90278-L